User profiles for H. Hackl
Hubert HacklMedical University of Innsbruck Verified email at i-med.ac.at Cited by 15303 |
Computational genomics tools for dissecting tumour–immune cell interactions
Recent breakthroughs in cancer immunotherapy and decreasing costs of high-throughput
technologies have sparked intensive research into tumour–immune cell interactions using …
technologies have sparked intensive research into tumour–immune cell interactions using …
ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks
We have developed ClueGO, an easy to use Cytoscape plug-in that strongly improves
biological interpretation of large lists of genes. ClueGO integrates Gene Ontology (GO) terms as …
biological interpretation of large lists of genes. ClueGO integrates Gene Ontology (GO) terms as …
Next-generation computational tools for interrogating cancer immunity
The remarkable success of cancer therapies with immune checkpoint blockers is
revolutionizing oncology and has sparked intensive basic and translational research into the …
revolutionizing oncology and has sparked intensive basic and translational research into the …
[PDF][PDF] Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade
The Cancer Genome Atlas revealed the genomic landscapes of human cancers. In parallel,
immunotherapy is transforming the treatment of advanced cancers. Unfortunately, the …
immunotherapy is transforming the treatment of advanced cancers. Unfortunately, the …
[HTML][HTML] Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia
H Hackl, K Astanina, R Wieser - Journal of hematology & oncology, 2017 - Springer
Background The majority of individuals with acute myeloid leukemia (AML) respond to initial
chemotherapy and achieve a complete remission, yet only a minority experience long-term …
chemotherapy and achieve a complete remission, yet only a minority experience long-term …
[HTML][HTML] Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data
We introduce quanTIseq, a method to quantify the fractions of ten immune cell types from bulk
RNA-sequencing data. quanTIseq was extensively validated in blood and tumor samples …
RNA-sequencing data. quanTIseq was extensively validated in blood and tumor samples …
[HTML][HTML] Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for …
… Major differences in the enrichment of TIL subpopulations could be observed in the MSI-H,
MSS^, and the four MSS subtypes. MSI-H tumors were enriched with all CD4 and CD8 …
MSS^, and the four MSS subtypes. MSI-H tumors were enriched with all CD4 and CD8 …
[PDF][PDF] Lipocalin 2 protects from inflammation and tumorigenesis associated with gut microbiota alterations
High mucosal and fecal concentrations of the antimicrobial siderophore-binding peptide
Lipocalin-2 (Lcn2) are observed in inflammatory bowel disease. However, Lcn2 function in …
Lipocalin-2 (Lcn2) are observed in inflammatory bowel disease. However, Lcn2 function in …
Interfacial microstructure and mechanical properties of aluminium–zinc-coated steel joints made by a modified metal inert gas welding–brazing process
HT Zhang, JC Feng, P He, H Hackl - Materials characterization, 2007 - Elsevier
The microstructure and properties of aluminium–zinc coated steel lap joints made by a
modified metal inert gas CMT welding–brazing process was investigated. It was found that the …
modified metal inert gas CMT welding–brazing process was investigated. It was found that the …
[HTML][HTML] Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution
The cancer immunoediting hypothesis postulates a dual role of the immune system: protecting
the host by eliminating tumor cells, and shaping the tumor by editing its genome. Here, we …
the host by eliminating tumor cells, and shaping the tumor by editing its genome. Here, we …